Indication: Respiratory Distress Syndrome (RDS)

A Partially-Blind, Randomized, Controlled, Parallel-Group Dose Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFactTM (SF-RI 1 surfactant for inhalation combined with a dedicated drug delivery system) in Preterm Infants at Risk of

Sub-indication: Respiratory Distress Syndrome (RDS)

Drug Study

Principal Investigator: Tonya Robinson, M.D.
Norton Children's Neonatology, affiliated with the UofL School of Medicine

Sponsor: Aerogen Pharma Limited

Search our entire site.